Veytics Intelligence
2026-10-31 · NASDAQ

Is AbbVie a Buy After Its Latest Earnings Report?

Key PointsAdjusted EPS nearly doubled, but most of that comes from last year’s big research-deal charge, and underlying growth was closer to 17%.

Przeczytaj pelny brief Veytics

Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.